Piscataway, NJ. (PRWEB) June 04, 2014
Clearview Diagnostics, Inc. announced today that they have received FDA approval to market their imaging software system, ClearViewHD. The ClearView Image Enhancement System uses proprietary patent-pending technology to significantly enhance the ultrasound images used for breast cancer diagnosis. Ultrasound imaging is especially useful in women with dense breast tissue, found in up to 50% of the female population and especially prevalent in younger women, where traditional mammogram screening can fail to find the cancer.
Christine Podilchuk, Ph.D, the company’s CEO said she is excited to get this to market, recognizing that it will make an immediate positive impact for women and potential breast cancer patients. “We are inspired by the need to eradicate breast cancer, and our primary focus is on innovative image processing technology to assist the radiologist in early detection and accurate diagnosis of breast cancer to improve patient outcome and quality of life."
Founded by Professor Richard Mammone, Clearview Diagnostics, Inc. is located in Piscataway, NJ and is a Rutgers University tech start-up company. Clearview is uniquely positioned to collaborate with world-renowned hospitals, cancer centers and research facilities, as well as attract some of the most talented engineers and scientists in the country. The company has received funding and advisory support from River Styx Capital, an RRBB Accountants and Advisors affiliate. Larry Frankel of River Styx said, “Clearview is one of our most exciting projects, not only for the benefit it will have in breast cancer detection and cost reduction, but because of the speed with which the Clearview team delivered this transformative product” http://www.clearviewdiagnosticsinc.com.